These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 12501870)

  • 1. Immunogenicity of therapeutic proteins: clinical implications and future prospects.
    Schellekens H
    Clin Ther; 2002 Nov; 24(11):1720-40; discussion 1719. PubMed ID: 12501870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of biopharmaceuticals in laboratory animals.
    Wierda D; Smith HW; Zwickl CM
    Toxicology; 2001 Feb; 158(1-2):71-4. PubMed ID: 11164995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally engineered proteins or antibodies with absent or reduced immunogenicity.
    Tangri S; LiCalsi C; Sidney J; Sette A
    Curr Med Chem; 2002 Dec; 9(24):2191-9. PubMed ID: 12470241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumventing immunogenicity in the development of therapeutic antibodies.
    Holgate RG; Baker MP
    IDrugs; 2009 Apr; 12(4):233-7. PubMed ID: 19350467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-immunogenicity relationships of therapeutic proteins.
    Hermeling S; Crommelin DJ; Schellekens H; Jiskoot W
    Pharm Res; 2004 Jun; 21(6):897-903. PubMed ID: 15212151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the immunogenicity of therapeutic proteins.
    Schellekens H
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
    Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
    Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.
    Barbosa MD; Celis E
    Drug Discov Today; 2007 Aug; 12(15-16):674-81. PubMed ID: 17706550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of recombinant human proteins: causes and consequences.
    Schellekens H; Casadevall N
    J Neurol; 2004 Jun; 251 Suppl 2():II4-9. PubMed ID: 15264106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.
    Kuriakose A; Chirmule N; Nair P
    J Immunol Res; 2016; 2016():1298473. PubMed ID: 27437405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models as indicators of immunogenicity of therapeutic proteins in humans.
    Bussiere JL
    Dev Biol (Basel); 2003; 112():135-9. PubMed ID: 12762512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of bone morphogenetic proteins.
    Hwang CJ; Vaccaro AR; Lawrence JP; Hong J; Schellekens H; Alaoui-Ismaili MH; Falb D
    J Neurosurg Spine; 2009 May; 10(5):443-51. PubMed ID: 19442006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity of therapeutic proteins.
    Schellekens H
    Discov Med; 2010 Jun; 9(49):560-4. PubMed ID: 20587346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
    van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.
    Torosantucci R; Brinks V; Kijanka G; Halim LA; Sauerborn M; Schellekens H; Jiskoot W
    J Pharm Sci; 2014 May; 103(5):1367-74. PubMed ID: 24619587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prediction of immunogenicity of therapeutic proteins].
    Maillère B; Delluc S; Ravot G
    Med Sci (Paris); 2012 Jan; 28(1):82-8. PubMed ID: 22289835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.